HB783 would add new sections to the Ohio Revised Code requiring health care providers to give specific notice to patients before and after dispensing mifepristone for a chemical abortion. The bill states that, unless there is a medical emergency, providers must tell the patient that it may be possible to reverse the intended effects of a chemical abortion before taking misoprostol, and must provide printed discharge instructions containing a state hotline, a state web site, and a detailed message encouraging the patient to seek abortion pill reversal services. The bill also directs the Ohio Department of Health to create and maintain a “stable web site,” a 24/7 hotline, public education materials, provider resources, annual reporting, and a fund to support these activities.
The bill creates a civil enforcement scheme. The woman, the biological father, and in some cases grandparents may sue a provider for violating the notice requirements, and the attorney general or a prosecutor may also bring a civil action and seek penalties. Providers or their agents could face daily civil penalties and additional penalties for knowing violations, while the bill bars penalties against the pregnant woman herself. It also restricts state contracts for the program from going to organizations that provide, promote, counsel, or refer for abortion-related services.
In terms of state law impact, HB783 would add a new regulatory and informational framework around chemical abortions and would expand the Department of Health’s duties to include public messaging, hotline operation, website maintenance, reporting, and funding administration. It would also create a new state fund, the unborn child education and public information fund, to pay for the website, hotline, outreach materials, technology, and provider training support. The bill delays enforcement until the Department of Health posts the required web information.
Because the bill was only introduced and has no recorded votes or committee testimony in the provided materials, there is no formal voting history to gauge legislative sentiment. Based on the bill text alone, the measure appears strongly supportive of abortion pill reversal efforts and is framed as a patient-information and public-awareness bill. The absence of committee discussion means there is no recorded in-context support or opposition beyond the bill’s own language.
The main points of contention likely concern the bill’s medical claims, compelled speech requirements for providers, and the use of state resources to promote abortion pill reversal. Critics would likely object to the requirement that providers deliver a specific message about reversal and to the bill’s assertion that studies show abortion pill reversal is safe and effective, while supporters would likely argue that the bill increases informed consent and gives patients an additional option if they change their minds. The exclusion of abortion providers and related organizations from state contracts is another likely source of dispute.
HB783 would amend Ohio law by creating sections 2317.57 and 2317.571 of the Revised Code, imposing new notice obligations on providers who dispense mifepristone for chemical abortions, establishing civil liability and penalties for noncompliance, and directing the Department of Health to run a statewide abortion pill reversal information program. It would also create the unborn child education and public information fund and authorize the department to use those funds for web, hotline, outreach, and training activities, while limiting contracts to entities that do not provide or refer for abortion services.
The bill’s text reflects a clear pro-life and abortion-pill-reversal orientation, with the stated purpose of informing patients that reversal may be possible and providing state-supported access to related information and referrals. Because there are no committee transcripts or votes in the provided record, there is no documented legislative debate to measure support or opposition. The available context suggests the bill was introduced in a committee setting but had not yet advanced or been publicly contested in the materials provided.
Likely points of contention include whether abortion pill reversal is medically established, whether the bill compels providers to deliver a state-scripted message, and whether the state should fund and promote a program that excludes abortion providers and affiliated organizations. Opponents would likely focus on the accuracy of the required statements, patient autonomy, and the use of civil penalties, while supporters would likely emphasize informed consent, patient choice, and the opportunity for a patient to change her mind before taking misoprostol.